2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100446
    NTU281 815619-12-6 98%
    NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes.
    NTU281
  • HY-10061A
    Lesogaberan napadisylate 477956-38-0 98%
    Lesogaberan (AZD-3355) napadisylate is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptors. The affinity (Kis) of Lesogaberan napadisylate for rat GABAB and GABAA receptors, as measured by displacement of [3H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan napadisylate inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
    Lesogaberan napadisylate
  • HY-100787
    L-Cysteine S-sulfate sodium 7381-67-1 98%
    L-Cysteine S-sulfate sodium is an S-sulfated derivative of L-cysteine (HY-Y0337). L-Cysteine S-sulfate sodium is the substrate for cystine lyase, it can be used in mass spectrometry and chromatography analyses.
    L-Cysteine S-sulfate sodium
  • HY-100819
    RO5234444 1365266-79-0 98%
    RO5234444 is an orally active CCR2 antagonist, with IC50s of 22nM for human CCR2 and 161 nM for mouse CCR2. RO5234444 alleviates glomerulosclerosis, reduces albuminuria, and significantly improves the glomerular filtration rate (GFR) in the uninephrectomized (1K) type 2 diabetic db/db mouse model. RO5234444 can be used for the study of type 2 diabetic nephropathy.
    RO5234444
  • HY-100899
    Heparastatin 153758-25-9 98%
    Heparastatin is a heparanase inhibitor.
    Heparastatin
  • HY-100969
    EBPC 4450-98-0 98%
    EBPC is a potent and selective aldose reductase inhibitor with an IC50 of 47 nM.
    EBPC
  • HY-101048
    Synthalin A sulfate 182285-12-7 98%
    Synthalin A sulfate is a biguanylated diamine with antibacterial and hypoglycemic properties. Synthalin A sulfate against S. aureus with a MIC of 64 μg/mL.
    Synthalin A sulfate
  • HY-101076
    L-690488 142523-14-6 98%
    L-690488 is a proagent of L-690330 and is a selective inositol monophosphatase (IMPase) inhibitor. L-690488 has more effective cell penetration than L-690330.
    L-690488
  • HY-101122
    LX2761 1610954-97-6 98%
    LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC50 values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research.
    LX2761
  • HY-101203
    GJ103 1459687-89-8 98%
    GJ103 is a read-through compound that can induce read through of premature stop codons. GJ103 has potential for the research of genetic disorders caused by nonsense mutations.
    GJ103
  • HY-101227
    (±)-threo-3-Methylglutamic acid 63088-04-0 98%
    (±)-threo-3-Methylglutamic acid is a potent EAAT2/4 inhibitor. (±)-threo-3-Methylglutamic acid also is an ionotropic glutamate receptor agonist. (±)-threo-3-Methylglutamic acid inhibits glutamate uptake by rod outer segments.
    (±)-threo-3-Methylglutamic acid
  • HY-101393
    CGP 12177 81047-99-6 98%
    CGP 12177 ((±)-CGP 12177) is a β-Adrenergic receptor (β-AR) ligand. CGP 12177 is a β3-AR (Ki = 88 nM) agonist with β1/β2-AR (Ki = 0.9 nM for β1; Ki = 4 nM for β2) antagonist action. CGP 12177 exhibits partial agonist properties for α1-AR in rat pulmonary artery. CGP 12177 regulates the expression of ucp and leptin genes in NMRI mice adipose tissues. CGP 12177 can be used for cardiovascular and metabolic disease research.
    CGP 12177
  • HY-101555
    M 16209 128851-36-5 98%
    M 16209 is an orally active aldose reductase (AR) inhibitor. M 16209 inhibits partially purified AR from various sources with IC50 values of 0.12, 0.24, 4.5, 1.2 and 9.3 μM for rat lens AR, bovine lens AR, bovine kidney AR, canine lens AR and human placental AR. M 16209 can be used for the research of metabolic disease, such as diabetes.
    M 16209
  • HY-101637
    Reglitazar 170861-63-9 98%
    Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels.
    Reglitazar
  • HY-101692
    AZ-1355 75451-07-9 98.19%
    AZ-1355 is an orally active and effctive lipid-lowering agent. AZ-1355 inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro.
    AZ-1355
  • HY-101699
    AMG-076 free base 693823-79-9 98%
    AMG-076 free base is an orally bioavailable and selective MCHR1 antagonist. AMG-076 free base results in significant reduction in body weight gain in nonobese mice fed a high-fat diet and in high-fat diet-induced obese (DIO) mice.
    AMG-076 free base
  • HY-101738
    Peliglitazar 331744-64-0 98%
    Peliglitazar is a dual α/γ PPAR activator.
    Peliglitazar
  • HY-101758
    BM-131246 103787-97-9 98%
    BM-131246 is an oral antidiabetic agent.
    BM-131246
  • HY-101824
    NC-2100 179068-64-5 98%
    NC-2100 is a PPAR activator. NC-2100 can effectively reduce the plasma glucose and triglyceride levels of obese KKAy mice. NC-2100 can induce UCP1 and UCP2 expression in mesenteric and subcutaneous WAT of mice. NC-2100 can be used in research related to type 2 diabetes.
    NC-2100
  • HY-101962
    HNMPA 132541-52-7 98%
    HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities
    HNMPA
Cat. No. Product Name / Synonyms Application Reactivity